Colgate-Palmolive Company
CL
$89.92
+2.03%
Colgate-Palmolive Company is a global leader in the Household & Personal Products industry, manufacturing and selling a wide range of essential consumer goods including oral care (its namesake Colgate brand), personal care, home care, and pet nutrition through its Hill's brand. The company is a dominant, established player with a vast international footprint, deriving about 70% of its sales from outside the U.S., which provides both stability and exposure to emerging market growth. The current investor narrative centers on its role as a classic defensive stock during market rotations, with recent news highlighting a shift from growth to value, placing focus on its ability to deliver consistent, albeit moderate, growth and robust cash flows in an uncertain economic environment, while managing inflationary cost pressures.…
CL
Colgate-Palmolive Company
$89.92
CL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $116.90 and implied upside of +30.0% versus the current price.
Average Target
$116.90
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$72 - $117
Analyst target range
Analyst coverage for Colgate-Palmolive is limited in the provided data, with only 5 analysts contributing to estimates, which is below the typical coverage for a large-cap company of its size and suggests the stock may be under-followed or that consensus data is incomplete. The consensus sentiment, inferred from recent institutional ratings, leans bullish, with firms like Deutsche Bank (upgraded to Buy), Citigroup (Buy), JP Morgan (Overweight), and B of A Securities (Buy) maintaining positive ratings, though others like Barclays and Wells Fargo are at Equal Weight. The average target price and implied upside cannot be calculated from the given data.
The target price range and signal strength cannot be determined due to insufficient data in the analyst inputs. The recent pattern of institutional ratings shows an upgrade from Deutsche Bank in late March 2026 from Hold to Buy, which could signal a positive shift in sentiment following the stock's pullback. The implications of limited coverage include potentially higher volatility and less efficient price discovery, as fewer institutional eyes are scrutinizing the company's fundamentals, though its status as a mega-cap staple likely ensures some baseline level of attention.
Bulls vs Bears: CL Investment Factors
The evidence for Colgate-Palmolive presents a classic tension between quality and valuation. The bull case is strongly supported by the company's defensive characteristics, exceptional cash generation ($3.63B FCF), and premium profitability (60.1% gross margin), which are highly desirable in an uncertain economic climate. However, the bear case effectively highlights the stock's rich valuation (29.97x trailing PE) for its modest growth profile (5.78% YoY revenue growth) and elevated debt (147.9% D/E). Currently, the bear side has slightly stronger near-term evidence, as the stock's recent 8.83% pullback and high multiple suggest it is priced for perfection in a low-growth business. The single most important tension in the investment debate is whether the market will continue to pay a significant premium for Colgate's quality and stability, or if its low growth trajectory will inevitably lead to valuation compression towards sector averages.
Bullish
- Exceptional Cash Generation: The company generates massive free cash flow of $3.63 billion TTM, which provides a robust foundation for shareholder returns and financial flexibility. This strong cash flow supports a dividend with an 85.5% payout ratio and funds share buybacks, insulating the business from market volatility.
- Premium Profitability Margins: Colgate boasts industry-leading gross and operating margins of 60.1% and 21.3%, respectively, which provide a significant competitive moat and pricing power. These high margins are a key driver of its strong return on equity of 39.5% and justify a valuation premium.
- Defensive Profile & Low Volatility: With a beta of 0.304, CL is roughly 70% less volatile than the broader market, making it a classic defensive holding during economic uncertainty. This low volatility is attractive for risk-averse portfolios, especially in a market environment rotating towards value and stability.
- Strong International Growth Exposure: Approximately 70% of sales come from outside the U.S., with nearly half from emerging regions, providing a long-term growth runway beyond mature domestic markets. This global footprint diversifies revenue streams and offers exposure to faster-growing consumer bases.
Bearish
- Elevated Valuation on Trailing Basis: The stock trades at a trailing PE of 29.97x, which is high for a mature, low-growth consumer staples company and sits towards the upper end of its historical range. This premium valuation leaves little room for error and makes the stock susceptible to multiple compression if growth disappoints.
- Revenue Growth Deceleration: Q4 2025 revenue growth of 5.78% YoY represents a slowdown from stronger growth in prior 2025 quarters, reinforcing its identity as a low-to-mid single-digit growth company. In a market rewarding high growth, this modest trajectory may limit significant price appreciation.
- High Debt Load: The company carries a substantial debt-to-equity ratio of 147.9%, which, while common for cash-generative staples, increases financial risk in a rising interest rate environment. Although strong cash flow mitigates this risk, it limits financial flexibility for large-scale M&A.
- Limited Analyst Coverage & Data: With only 5 analysts providing estimates, coverage is thin for a mega-cap company, potentially leading to less efficient price discovery and higher volatility. The lack of a clear average target price and upside/downside quantification makes risk/reward assessment more ambiguous.
CL Technical Analysis
The stock is in a sustained uptrend over the past six months, evidenced by a 12.91% gain, but has recently experienced a significant pullback from its highs, trading down 8.83% over the last three months. Currently priced at $88.13, the stock sits approximately 54% above its 52-week low of $74.55 but 11% below its 52-week high of $99.33, indicating it has retreated from peak momentum levels and is now in a consolidation phase. Recent short-term momentum shows a modest recovery, with a 5.56% gain over the past month, which diverges positively from the negative 3-month performance and suggests a potential stabilization or attempt to regain its upward trajectory after the February-March correction.
Key technical support is anchored at the 52-week low area near $74.55, while immediate overhead resistance resides at the recent high of $99.33. A decisive breakout above $99.33 would signal a resumption of the primary bull trend, whereas a breakdown below the $74.55 support could indicate a deeper correction is underway. The stock exhibits very low market-relative volatility, with a beta of 0.304, meaning it is roughly 70% less volatile than the broader market (SPY), which is characteristic of a defensive consumer staples name and implies lower risk for position sizing but also less explosive upside during risk-on rallies.
Beta
0.30
0.30x market volatility
Max Drawdown
-21.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
-1.4%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +4.8% | +4.0% |
| 3m | -6.0% | +8.2% |
| 6m | +14.6% | +11.5% |
| 1y | -1.4% | +24.3% |
| ytd | +15.7% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue growth remains positive but modest, with Q4 2025 revenue of $5.23 billion representing a 5.78% year-over-year increase; however, this marks a deceleration from the stronger growth seen in prior quarters of 2025 (Q1: $4.91B, Q2: $5.11B, Q3: $5.13B). Segment data shows the core Oral, Personal and Home Care segment ($4.03B in Q4) is the larger driver, while the Pet Nutrition segment ($1.20B) provides a stable, premium growth component. This trajectory suggests Colgate is a low-to-mid single-digit organic growth company, consistent with its mature market position.
The company's profitability is robust on an underlying basis, with a gross margin of 60.15% in Q4 2025, though the quarter showed a net loss of $37 million due to significant one-time other expenses of $970 million; excluding this, operating income was a healthy $1.08 billion, translating to a 20.59% operating margin. Trailing twelve-month free cash flow is a substantial $3.63 billion, indicating strong cash generation. The net margin for the period was -0.71%, but the trailing net margin from valuation data is a healthy 10.46%, highlighting the anomalous nature of the Q4 result.
Financial health is sound with ample liquidity, evidenced by a current ratio of 1.00, though the debt-to-equity ratio is elevated at 147.93%, which is common for mature, cash-generative companies in this sector that leverage balance sheets for shareholder returns. The strong free cash flow of $3.63 billion comfortably covers dividend payments (payout ratio of 85.5%) and share buybacks, reducing reliance on external financing and mitigating the high debt level.
Quarterly Revenue
$5.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given the positive net income on a trailing basis (net margin of 10.46%), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 29.97x, which is significantly higher than the forward PE of 21.81x, indicating the market expects meaningful earnings growth and normalization from the anomalous Q4 loss, with forward estimates implying a 27% increase in earnings.
Compared to sector averages, Colgate's valuation presents a mixed picture; its forward PE of 21.81x is above the typical market multiple for defensive staples, but direct industry average data is not provided in the inputs for a precise comparison. The premium is likely justified by its industry-leading margins (60.1% gross, 21.3% operating), strong global brand equity, and consistent dividend payer status, which command a quality and stability premium among investors.
Historically, the current trailing PE of 29.97x is below the extreme highs seen in recent quarters (e.g., 350+ in Q4 2024) which were distorted by accounting effects, but it remains towards the upper end of its multi-year range when excluding outliers. This suggests the stock is not cheap on an absolute historical basis, and much of its future price appreciation is contingent on the company meeting the elevated earnings growth expectations embedded in the forward multiple.
PE
30.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -430x~3280x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate's primary financial risk stems from its elevated debt-to-equity ratio of 147.9%, which, while serviceable given its $3.63 billion TTM free cash flow, increases interest expense sensitivity and reduces balance sheet agility. Operationally, revenue growth deceleration to 5.78% YoY in Q4 2025 highlights the challenge of moving the needle for a $20+ billion revenue behemoth, creating dependence on pricing and margin expansion to drive earnings. Furthermore, the Q4 2025 net loss of $37 million, though due to a one-time $970 million expense, exposes investors to potential earnings volatility from non-operating items.
Market & Competitive Risks: The stock's forward PE of 21.81x, while lower than its trailing multiple, still likely represents a premium to many consumer staples peers, creating valuation compression risk if investor sentiment shifts away from defensive quality. Its extremely low beta of 0.304, while a defensive strength, also means it has significantly underperformed the SPY over the past year (-1.67% vs. +25.19%), posing a relative performance risk in sustained bull markets. Competitive risks are evergreen in fast-moving consumer goods, with private label incursion and digital-native brands potentially chipping away at pricing power in its core categories.
Worst-Case Scenario: The most damaging scenario would involve a simultaneous earnings miss, a guidance cut due to intensified inflation or recessionary pressures in key international markets, and a broad sector derating. This could trigger a rapid multiple compression from its current forward PE of 21.8x towards a market-average multiple, coupled with a decline in earnings estimates. A realistic downside target would be a retest of the 52-week low of $74.55, representing a potential loss of approximately -15% from the current price of $88.13. The historical max drawdown of -21.74% provides a boundary for the severity of such a correction.